A Study of Tirzepatide (LY3298176) in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes

NCT05536804 · Active, not recruiting

Last updated 2026-05-28

This clinical trial is testing the effects of tirzepatide in adults who have overweight or obesity along with chronic kidney disease, with or without type 2 diabetes.

Status Active, not recruiting Ongoing, but no longer enrolling new participants.

Phase Phase 2 Tests whether it works and watches safety in a moderate group.

Type Interventional (clinical trial)

Design Randomized, double-blind treatment study

Participants 140 people Planned (estimated).

Who can join Ages 18+ · all sexes

Timeline Started 2023-02 · est. completion 2026-10

Where 27 sites · Austria, Canada, Denmark, Mexico, Netherlands, United States

What this study is testing ClinicalTrials.gov NCT05536804 ↗

Description as written by the study sponsor.

We are doing this study to learn more about how tirzepatide may help fight chronic kidney disease in people with obesity with or without type 2 diabetes (T2D). The study will last about 56 weeks and include up to 12 visits.

Treatments tested

Tirzepatide Drug

Administered SC
Placebo Drug

Administered SC

Main thing measured	Percent Change from Baseline in Renal Sinus Fat Content (MRI)
Sponsor	Eli Lilly and Company
Conditions studied	Overweight, Obesity, Chronic Kidney Disease, Type 2 Diabetes, T2D
GLP-1 drugs	tirzepatide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT05536804 ↗